Search

Displaying results 1711 - 1720 of 10000 in total
  1. Drug

    Mifamurtide

    go.drugbank.com/drugs/DB13615
    ApprovedInvestigational

    While about 90% of patients with newly diagnosed osteosarcoma may achieve complete remission from first-line therapies, the prognosis is still poor for patients with non-metastatic osteosarcoma with lower … Also called L-MTP-PE, mifamurtide may be a liposomal form of of the active ingredient MTP-PE, which is a synthetic, less pyrogenic, and longer-acting derivative of muramyl dipeptide (MDP).

  2. Drug

    Ropeginterferon alfa-2b

    go.drugbank.com/drugs/DB15119
    ApprovedInvestigational

    [A242005] Ropeginterferon alfa-2b is a next-generation mono-pegylated type I interferon produced from proline-IFN-α-2b in _Escherichia coli_ that has high tolerability and a long half-life. … [A242015, L39170] Ropeginterferon alfa-2b has shown efficacy in PV in _in vitro_ and _in vivo_ models and clinical trials.

    Synonyms: PEG-P-IFN-alfa-2b, PEG-P-IFN-alpha-2bCategories: Interferon Type I
  3. Drug

    Tegafur-uracil

    go.drugbank.com/drugs/DB09327
    Approved

    Tegafur-uracil is an anti-tumor compound containing tegafur (1-(2-tetrahydrofuryl)-5-fluorouracil) and uracil in a molar ratio of 1:4. … It was developed as an anti-cancer therapy by Taiho Pharmaceutical Co Ltd.[A32073] It is approved in different countries but it is not yet approved by the FDA, Health Canada or EMA.

  4. Drug

    Nalmefene

    go.drugbank.com/drugs/DB06230
    ApprovedInvestigationalWithdrawn

    Nalmefene, a 6-methylene analogue of [naltrexone], is an opioid receptor antagonist. … [L40684] It acts as an antagonist at the mu (μ)-opioid and delta (δ)-opioid receptors and a partial agonist at the kappa (κ)-opioid receptor.

    Categories: Drugs Used in Alcohol Dependence, Drugs Used in Addictive Disorders
  5. Drug

    Chlordiazepoxide

    go.drugbank.com/drugs/DB00475
    ApprovedIllicit

    An anxiolytic benzodiazepine derivative with anticonvulsant, sedative, and amnesic properties. It has also been used in the symptomatic treatment of alcohol withdrawal.

    Mixtures: Limbitrol DS, AA PHARMA CHLORAX CAPSULE
  6. Drug

    Boceprevir

    go.drugbank.com/drugs/DB08873
    ApprovedWithdrawn

    In a joint recommendation published in 2016, the American Association for the Study of Liver Diseases (AASLD) and the Infectious Diseases Society of America (IDSA) do not reccomend Boceprevir in combination … with [DB00811], [DB00008], and [DB00022] as first line therapy for Hepatitis C [A19593].

    Categories: NS3/4A Protease Inhibitors, HCV NS3/4A Protease Inhibitors
  7. Drug

    Pimozide

    go.drugbank.com/drugs/DB01100
    Approved

    A diphenylbutylpiperidine that is effective as an antipsychotic agent and as an alternative to haloperidol for the suppression of vocal and motor tics in patients with Tourette syndrome. … Although the precise mechanism of action is unknown, blockade of postsynaptic dopamine receptors has been postulated. (From AMA Drug Evaluations Annual, 1994, p403)

    Categories: Dopamine D2 Receptor Antagonists, Cytochrome P-450 CYP1A2 Substrates with a Narrow Therapeutic Index
  8. Pathway

    Inositol Metabolism

    smpdb.ca/view/SMP0000011
    Metabolic

    Inositol is abundant in many commonly consumed foods such as bran-rich cereals, beans, nuts, and fruit (particularly cantaloupe, melons, and oranges). … The carbocyclic polyol inositol (otherwise known as myo-inositol) has a significant role in physiological systems as many secondary eukaryotic messengers derive their structure from inositol.

    Drugs: ATP · Calcium · Magnesium cation · Iron · 1D-myo-inositol 1,3,4-trisphosphate · Pyrophosphoric acid +1 more
    Enzymes: Activating molecule in BECN1-regulated autophagy protein 1
  9. Drug

    Olive oil

    go.drugbank.com/drugs/DB09567
    ApprovedInvestigational

    Used as a source of fatty acids in total parenteral nutrition and as an additive in some cosmetic products [FDA Label].

    Mixtures: CLINOLEIC %20 IV İNFÜZYONLUK LİPİD EMÜLSİYON, 100 ML, CLINOLEIC %20 IV İNFÜZYONLUK LİPİD EMÜLSİYON, 250 ML
  10. Drug

    Tivozanib

    go.drugbank.com/drugs/DB11800
    ApprovedInvestigational

    Renal cell carcinoma (RCC) is responsible for 3% of cancer cases[A231314] and is one of the 10 most common cancers in adults. The average age of diagnosis is between age 65 to 74. … It was approved on March 10, 2021 by the FDA. Marketed by Aveo Oncology, tivozanib is a promising therapy for individuals with RCC who have not been treated successfully with other therapies.[L32524]